LENZ Therapeutics (LENZ) News Today $23.49 -1.45 (-5.81%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$23.46 -0.02 (-0.11%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period LENZ Therapeutics (LENZ) to Release Quarterly Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings before the market opens on Wednesday, February 26, Financial Modeling Prep reports.February 21 at 2:21 AM | marketbeat.comLENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1kFebruary 19 at 2:15 PM | finance.yahoo.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024February 14, 2025 | investorplace.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.7% - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.7% - Time to Sell?February 10, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issuedFebruary 3, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading Up 8% - Here's WhyLENZ Therapeutics (NASDAQ:LENZ) Trading 8% Higher - What's Next?January 31, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for LENZ FY2025 Earnings?LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs cut their FY2025 earnings estimates for LENZ Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per shaJanuary 31, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1% - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1% - Should You Sell?January 29, 2025 | marketbeat.comLENZ Therapeutics (LENZ) Expected to Announce Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comLENZ Therapeutics, Inc. (LENZ)January 25, 2025 | ca.finance.yahoo.comBarclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Barclays PLC boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 273.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,463 shares of the company's stoJanuary 19, 2025 | marketbeat.comShort Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9%LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,530,000 shares, an increase of 11.9% from the December 15th total of 2,260,000 shares. Based on an average trading volume of 154,500 shares, the days-to-cover ratio is currently 16.4 days. Currently, 11.3% of the company's shares are short sold.January 18, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 5% - Time to Sell?LENZ Therapeutics (NASDAQ:LENZ) Shares Down 5% - What's Next?January 16, 2025 | marketbeat.comHarbor Capital Advisors Inc. Takes Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Harbor Capital Advisors Inc. bought a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 43,989 shares of theJanuary 13, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Trading Down 8.9% - Should You Sell?January 10, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from BrokeragesLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buyJanuary 9, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC lowered its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 6.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 338,024 shares of the company's stock afteJanuary 3, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1% - What's Next?December 31, 2024 | marketbeat.comState Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ)State Street Corp grew its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 18.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 289,154 shares of the company's stock after acquiring an additional 45,6December 28, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Trading 6.3% Higher - Here's What HappenedDecember 26, 2024 | marketbeat.comWellington Management Group LLP Takes $585,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Wellington Management Group LLP purchased a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 24,621 shares of the company's stock, valued at approximately $585,December 21, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.1% - Time to Sell?LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% - Should You Sell?December 20, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading 5.8% Higher - Time to Buy?LENZ Therapeutics (NASDAQ:LENZ) Shares Up 5.8% - Here's WhyDecember 19, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Charles Schwab Investment Management Inc. increased its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 197.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,371 shares ofDecember 16, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus rating of "Buy" from the seven analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating onDecember 15, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Invests $743,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)The Manufacturers Life Insurance Company bought a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 31,309 shares of the compaDecember 14, 2024 | marketbeat.com139,357 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 139,357 shares of the company's stock, valued at apDecember 4, 2024 | marketbeat.comWe're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash WiselyDecember 1, 2024 | finance.yahoo.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7% - Here's WhyLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.7% - Here's What HappenedNovember 29, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by BBR Partners LLCBBR Partners LLC increased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 100.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,000 shares of the coNovember 28, 2024 | marketbeat.comLENZ Therapeutics: Time For A PauseNovember 27, 2024 | seekingalpha.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.3% - Here's WhyLENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3% - What's Next?November 15, 2024 | marketbeat.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 15, 2024 | investorplace.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 12, 2024 | investorplace.comLENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year High - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Reaches New 1-Year High - Here's What HappenedNovember 12, 2024 | marketbeat.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 11, 2024 | investorplace.comLeerink Partnrs Brokers Boost Earnings Estimates for LENZLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs raised their Q4 2024 earnings per share estimates for LENZ Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earninNovember 11, 2024 | marketbeat.comHC Wainwright Has Positive Forecast for LENZ FY2024 EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst M. Caufield now anticipates that the company wNovember 11, 2024 | marketbeat.comFY2024 EPS Estimate for LENZ Therapeutics Boosted by AnalystLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair boosted their FY2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a report issued on Wednesday, November 6th. William Blair analyst L. Hanbury-Brown now expects that the company wiNovember 11, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comPatent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial StabilityNovember 8, 2024 | markets.businessinsider.comLENZ Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comLenz Therapeutics price target raised to $36 from $32 at LeerinkNovember 7, 2024 | markets.businessinsider.comLENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comLENZ Therapeutics (LENZ) Set to Announce Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)October 30, 2024 | markets.businessinsider.comLENZ reports positive Chinese study data for far-sightedness drugOctober 29, 2024 | msn.comLENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In ChinaOctober 28, 2024 | markets.businessinsider.comWhy LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketOctober 28, 2024 | benzinga.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼0.230.60▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼22▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News Today MRUS News Today BEAM News Today IBRX News Today ARWR News Today HCM News Today EWTX News Today MIRM News Today AMRX News Today KYMR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
